Japan Chemical Research Co. has completed a plant with up to three culture vessels containing 2.000 L volume each, to be used to produce recombinant therapeutic enzymes. The product pipeline includes human iduronate 2-sulfatase for the treatment of Hunter’s disease, human alpha-galactosidase A for the treatment of Fabry’s-disease, and human glucocerebrosidase for the treatment of Gaucher’s disease

Nikkei Biotech, June 24, 2013